SCVC, a Bristol, UK-based early-stage tech VC, announced the first close of its second fund, with a target of up to $100m.
The new fund builds on the team’s core strategy and expertise, investing at pre-seed and seed stage with initial cheque sizes of $500K up to $3M. It will also provide follow-on funding of Series A tickets up to $7M for performing companies.
The capital has already been deployed in processor technology startup VyperCore.
Co-founded by Dr. Harry Destecroix and Jon Craton, SCVC is an early-stage vc firm investing in technologies from biotech to quantum tech, partnering with companies aligned with its mission of improving the health of people and the health of the planet.
In addition, SCVC appointed exited founder John Williams as Venture Partner.
SCVC’s first $17m seed fund has backed 12 companies working on everything from therapeutics and diagnostics to quantum sensors and semiconductors. Recent investments include Delta g, which is pioneering a new generation of quantum gravity sensors, and Isomab, a pre-clinical stage biotech developing a breakthrough treatment for Peripheral Vascular Disease.
FinSMEs
14/09/2023